Golcadomide
- Generic Name
- Golcadomide
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30FN5O5
- CAS Number
- 2379572-34-4
- Unique Ingredient Identifier
- 29HLR8Z5BR
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT06035497
- Locations
- 🇯🇵
Anjo Kosei Hospital, Anjo-shi, Aichi, Japan
🇯🇵Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
Treatment of Newly-diagnosed Follicular Lymphoma with CELMoD Golcadomide, Rituximab +/- Nivolumab.
- Conditions
- Follicular Lymphoma Stage IIIFollicular Lymphoma Stage IVFollicular Lymphoma Stage II
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05788081
- Locations
- 🇦🇺
Grampians Health, Ballarat, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
🇦🇺University Hospital Geelong, Barwon Health, Geelong, Victoria, Australia
A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT05567510
- Locations
- 🇺🇸
Labcorp Clinical Research Unit - Madison, Madison, Wisconsin, United States
A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT05350800
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre /ID# 243262, Madrid, Spain
🇭🇺Debreceni Egyetem-Klinikai Kozpont /ID# 242450, Debrecen, Hajdu-Bihar, Hungary
🇭🇺Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 245935, Kaposvár, Somogy, Hungary
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sourasky Medical Center, Tel-Aviv, Israel
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- 🇬🇷
Local Institution - 703, Patras, Greece
🇨🇳Taichung Veterans General Hospital, Taichung City, Taiwan
🇺🇸Mayo Clinic - Arizona, Scottsdale, Arizona, United States
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT04434196
- Locations
- 🇺🇸
Local Institution - 104, Columbus, Ohio, United States
🇺🇸Local Institution - 106, Boston, Massachusetts, United States
🇺🇸Local Institution - 101, Portland, Oregon, United States
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 438
- Registration Number
- NCT03930953
- Locations
- 🇺🇸
Local Institution - 114, Los Angeles, California, United States
🇩🇰Rigshospitalet University Hospital, Copenhagen, Denmark
🇩🇰Local Institution - 603, Vejle, Denmark
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- 🇺🇸
Local Institution - 015, Omaha, Nebraska, United States
🇺🇸Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 011, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.